PDF(Pubmed)
Abstract：
UNASSIGNED: According to many previous studies, neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR) and hypersensitive C-reactive protein (CRP) are commonly used as important indicators to assess the prognosis of intravenous thrombolysis in AIS patients. Based on this, we used two novel biomarkers C-NLR (CRP/neutrophil-to-lymphocyte ratio) and C-LMR (CRP×lymphocyte-to-monocyte ratio) to investigate their correlation with 90-day outcomes in AIS patients after intravenous thrombolysis.
UNASSIGNED: A total of 204 AIS patients who received intravenous thrombolysis at the Stroke Center of Jiangsu Province Hospital of Chinese Medicine from January 2021 to December 2022 were retrospectively included. All patients were followed up 90 days after thrombolysis to assess their prognosis. Patients with a modified Rankin scale score (mRS) of 3-6 were included in the unfavorable outcome group, and those with a score of 0-2 were included in the favorable outcome group. Logistic regression analysis, receiver operating characteristic (ROC) curve, and Kaplan-Meier survival curve were used to investigate the association between C-NLR, C-LMR, and 90-day prognosis in AIS patients treated with early intravenous thrombolysis.
UNASSIGNED: C-NLR (OR=1.586, 95% CI=1.098~2.291, P=0.014) and C-LMR (OR=1.099, 95% CI=1.025~1.179, P=0.008) were independent risk factors for 90-day prognosis of AIS patients treated with early intravenous thrombolysis. The higher C-NLR and C-LMR were associated with unfavorable prognosis.
UNASSIGNED: C-NLR and C-LMR can be used as biomarkers to predict prognosis of AIS patients treated with early intravenous thrombolysis.
UNASSIGNED: A total of 204 AIS patients who received intravenous thrombolysis at the Stroke Center of Jiangsu Province Hospital of Chinese Medicine from January 2021 to December 2022 were retrospectively included. All patients were followed up 90 days after thrombolysis to assess their prognosis. Patients with a modified Rankin scale score (mRS) of 3-6 were included in the unfavorable outcome group, and those with a score of 0-2 were included in the favorable outcome group. Logistic regression analysis, receiver operating characteristic (ROC) curve, and Kaplan-Meier survival curve were used to investigate the association between C-NLR, C-LMR, and 90-day prognosis in AIS patients treated with early intravenous thrombolysis.
UNASSIGNED: C-NLR (OR=1.586, 95% CI=1.098~2.291, P=0.014) and C-LMR (OR=1.099, 95% CI=1.025~1.179, P=0.008) were independent risk factors for 90-day prognosis of AIS patients treated with early intravenous thrombolysis. The higher C-NLR and C-LMR were associated with unfavorable prognosis.
UNASSIGNED: C-NLR and C-LMR can be used as biomarkers to predict prognosis of AIS patients treated with early intravenous thrombolysis.
摘要：
■根据以前的许多研究，中性粒细胞与淋巴细胞比率（NLR），淋巴细胞与单核细胞比值(LMR)和超敏C反应蛋白(CRP)是评价AIS患者静脉溶栓预后的重要指标。基于此,我们使用了两种新的生物标志物C-NLR(CRP/中性粒细胞与淋巴细胞的比值)和C-LMR(CRP×淋巴细胞与单核细胞的比值)来研究它们与AIS患者静脉溶栓后90天结局的相关性.
■回顾性纳入2021年1月至2022年12月在江苏省中医院卒中中心接受静脉溶栓治疗的204例AIS患者。所有患者在溶栓后90天随访以评估其预后。改良Rankin量表评分（mRS）为3-6的患者纳入不良结局组，评分为0~2分的患者被纳入有利结局组.Logistic回归分析,接收机工作特性(ROC)曲线,和Kaplan-Meier存活曲线用于研究C-NLR之间的关联，C-LMR,接受早期静脉溶栓治疗的AIS患者的90天预后。
■C-NLR(OR=1.586,95%CI=1.098~2.291,P=0.014)和C-LMR(OR=1.099,95%CI=1.025~1.179,P=0.008)是AIS患者早期静脉溶栓后90天预后的独立危险因素。较高的C-NLR和C-LMR与预后不良相关。
■C-NLR和C-LMR可作为预测早期静脉溶栓治疗AIS患者预后的生物标志物。
■回顾性纳入2021年1月至2022年12月在江苏省中医院卒中中心接受静脉溶栓治疗的204例AIS患者。所有患者在溶栓后90天随访以评估其预后。改良Rankin量表评分（mRS）为3-6的患者纳入不良结局组，评分为0~2分的患者被纳入有利结局组.Logistic回归分析,接收机工作特性(ROC)曲线,和Kaplan-Meier存活曲线用于研究C-NLR之间的关联，C-LMR,接受早期静脉溶栓治疗的AIS患者的90天预后。
■C-NLR(OR=1.586,95%CI=1.098~2.291,P=0.014)和C-LMR(OR=1.099,95%CI=1.025~1.179,P=0.008)是AIS患者早期静脉溶栓后90天预后的独立危险因素。较高的C-NLR和C-LMR与预后不良相关。
■C-NLR和C-LMR可作为预测早期静脉溶栓治疗AIS患者预后的生物标志物。
